ClinicalTrials.gg
CompletedNCT06496607RAINIERUpdated Oct 28, 2026

A Study to Evaluate Solriktug in Adult Participants With Asthma

A Phase 2 interventional study of NSI-8226 and NSI-8226 in Asthma, sponsored by Uniquity One (UNI). Completed at 69 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Uniquity One (UNI) · Phase 2, Interventional, and Treatment

Updated Oct 28, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
585th of 1,353
145 · median 100
Started
2024
with 50 others
Phase 2
292 of 1,695
22 open now
Registered
1,587th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 585th largest by enrollment of the 1,353 interventional ones that give a count, is one of 51 that started in 2024, is one of 292 in phase 2, and was the 1,587th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.

Read the detailed description

This is a 12-week randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of 3 dose levels of solrikitug versus placebo on top of standard of care in adult participants with asthma.

Approximately 140 adult participants with asthma will be randomized. Participants will receive solrikitug, or placebo, administered via subcutaneous injection at the study site, over a 12-week treatment period. The study also includes a post-treatment follow-up period of 16 weeks.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Participant must be aged 18 to 75 years of age.
  • Documented diagnosis of asthma at least 12 months prior to Screening.
  • Participants must be on maintenance asthma medications, for at least 3 months prior to screening: inhaled (ICS) in combination with long-acting beta agonist (LABA), or as part of an approved triple therapy for asthma (ICS/LABA/long-acting muscarinic antagonist [LAMA]).
  • Participant has an ACQ-6 score ≥1.5 at Screening Visit.
  • Participant has of ≥50% to 90%, inclusive, of predicted normal value at Screening Visit 1.
  • Evidence of asthma as documented by reversibility in FEV1 of ≥12% and ≥200 mL over the pre-salbutamol FEV1 at Screening Visit.

Key exclusion criteria:

  • Female participant who is pregnant or breastfeeding.
  • Participant is a current smoker, or former smoker with a smoking history of ≥10 pack-years.
  • Participant has a known to any component of the formulation of solrikitug, including any of the , or a history of anaphylactic reaction to any therapeutic monoclonal antibody.
  • Participant has history or evidence of any cardiovascular, hematologic, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, renal and/or other major disease or , or any other condition (risks factors of pneumonia) that in the opinion of the Investigator might obfuscate the study data.
  • Participant has an exacerbation of asthma requiring use of OCS or hospitalization in the 6 weeks prior to Screening or during the Screening Period.
  • Participant has history or evidence of any clinically significant pulmonary condition, other than asthma.
  • Lower respiratory tract infection within the 6 weeks prior to Screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Solrikitug low dose subcutaneous injection

    Solrikitug

    Biological: NSI-8226

  • Experimental
    Solrikitug mid dose subcutaneous injection

    Solrikitug

    Biological: NSI-8226

  • Experimental
    Solrikitug high dose subcutaneous injection

    Solrikitug

    Biological: NSI-8226

  • Placebo comparator
    Placebo subcutaneous injection

    Placebo

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the effect of multiple doses of solrikitug on blood eosinophil counts compared with placebo

    Change from baseline in blood eosinophil counts evaluated over Weeks 8 to 12

    Time frame: Over weeks 8 and 12

Secondary outcomes

  1. To assess the safety and tolerability of multiple doses of solrikitug

    Adverse events (AEs) and serious adverse events (SAEs)

    Time frame: To week 12

07

Study locations

69 sites
  • Velocity Clinical Research
    Mobile, Alabama 36608, United States
  • Phoenix Medical Group
    Peoria, Arizona 85381, United States
  • Warren W. Pleskow, M.D.
    Encinitas, California 92024, United States
  • Beach Physicians Clinical Research Corp.
    Huntington Beach, California 92647, United States
  • Biosolutions Clinical Research Center
    La Mesa, California 91942, United States
  • Orso Health
    Long Beach, California 90808, United States
  • Downtown LA Research Center
    Los Angeles, California 90017, United States
  • Newport Native MD, Inc.
    Newport Beach, California 92663, United States
  • Prospective Research Innovations Inc.
    Rancho Cucamonga, California 91730, United States
  • Allergy & Asthma Medical Group and Research Center
    San Diego, California 92123, United States
  • Allergy & Asthma Associates of Santa Clara Valley
    San Jose, California 95117, United States
  • San Jose Clinical Trials
    San Jose, California 95128, United States
  • North Bay Clinical Research
    Santa Rosa, California 95405, United States
  • Providere Research
    West Covina, California 91790, United States
  • Velocity Clinical Research - Denver
    Englewood, Colorado 80110, United States
  • JY Research Institute
    Cutler Bay, Florida 33189, United States
  • Hillcrest Medical Research, LLC
    DeLand, Florida 32720, United States
  • Clinical Site Partners LLC dba-Leesburg
    Leesburg, Florida 34748, United States
  • Pharmax Research of South Florida
    Miami, Florida 33126, United States
  • Coral Research Clinic Corp.
    Miami, Florida 33186, United States
  • Pro-Care Research Center, Corp.
    Miami Gardens, Florida 33014, United States
  • Ogden Clinical Canyon View
    Tallahassee, Florida 32308, United States
  • Care Access, Tamarac
    Tamarac, Florida 33321, United States
  • TBC Research
    Tamarac, Florida 33321, United States
  • National Clinical Trials
    Cordele, Georgia 31015, United States
  • CPCC - Research, LLC
    East Point, Georgia 30344, United States
  • Aeroallergy Research Laboratories of Savannah, Inc.
    Savannah, Georgia 31406, United States
  • NexGen Research
    Boise, Idaho 83706, United States
  • Treasure Valley Medical Research
    Boise, Idaho 83706, United States
  • Accellacare - Duly
    Winfield, Illinois 60190, United States
  • Velocity Clinical Research - Sioux City
    Sioux City, Iowa 51106, United States
  • Velocity Clinical Research
    Lafayette, Louisiana 70508, United States
  • Chesapeake Clinical Research, Inc.
    White Marsh, Maryland 21162, United States
  • Mayflower Clinical
    South Dartmouth, Massachusetts 02747, United States
  • Deerborn Clinic
    Dearborn, Michigan 48126, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Pulmonary Research Institute of SE Michigan
    Farmington Hills, Michigan 48336, United States
  • Revive Research Institute, Inc.
    Southfield, Michigan 48075, United States
  • Montana Medical Research, Inc.
    Missoula, Montana 59808, United States
  • Henderson Trials
    Henderson, Nevada 89052, United States
  • A1 Clinical
    Queens Village, New York 11428, United States
  • Asheville Clinical Research
    Asheville, North Carolina 28803, United States
  • North Carolina Clinical Research
    Raleigh, North Carolina 27607, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • Midwest Clinical Research
    Dayton, Ohio 45417, United States
  • Toledo Institute of Clinical Research Inc.
    Toledo, Ohio 43617, United States
  • OK Clinical Research
    Edmond, Oklahoma 73034, United States
  • Velocity Clinical Research
    Medford, Oregon 97504, United States
  • Northwest Research Center
    Portland, Oregon 97202, United States
  • Clinical Research Associates of Central PA
    DuBois, Pennsylvania 15801, United States
  • Allergy & Asthma Diagnostic Treatment Center
    Lancaster, Pennsylvania 17601, United States
  • Temple University - Shenoy
    Philadelphia, Pennsylvania 19140, United States
  • Care Access - Mauldin
    Mauldin, South Carolina 29662, United States
  • Allergy, Asthma & Sinus Center, LLC
    Myrtle Beach, South Carolina 29588, United States
  • MBR - Charleston
    North Charleston, South Carolina 29406, United States
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
  • Premier Research Center, LLC
    Hendersonville, Tennessee 37075, United States
  • New Phase Research & Development
    Knoxville, Tennessee 37909, United States
  • TTS Research
    Boerne, Texas 78006, United States
  • Proactive RGV
    Brownsville, Texas 78520, United States
  • Ten20 Clinical Research, LLC
    Carrollton, Texas 75010, United States
  • Javarra Research
    Conroe, Texas 77384, United States
  • Dallas Allergy and Asthma Center
    Dallas, Texas 75231, United States
  • IntraCare Health Center
    Dallas, Texas 75254, United States
  • US Allergy & Asthma
    Frisco, Texas 75035, United States
  • IntraCare Clinical
    Greenville, Texas 75401, United States
  • Axsendo Clinical Research
    Houston, Texas 77002, United States
  • Gulf Coast Clinical Research
    Houston, Texas 77070, United States
  • Velocity Clinical Research - Hampton
    Hampton, Virginia 23666, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jul 2026, 23 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 23 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 11, 2024
StartActual
Jul 26, 2024
Primary completionActual
Jul 6, 2026
CompletionActual
Oct 26, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06496607
Lead sponsor
Uniquity One (UNI)
Collaborators
DevPro Biopharma
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Jul 26, 2024
Primary completion
Jul 6, 2026
Completion
Oct 26, 2026
Last update
Oct 28, 2026

Study contacts

Andrew W Lee, MD
study director · Vice President, Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solrikitug

Start the discussion